Статья
Оценка эндотелиальной дисфункции и возможности ее коррекции на современном этапе у больных сердечно-сосудистыми заболеваниями
В обзоре изложено современное представление о дисфункции эндотелия, способах ее оценки, подчеркнуты достоинства и недостатки различных методик. Показана роль оксида азота и эндотелина как важных маркеров эндотелиальной дисфункции, а также описаны методы их определения в клинической практике. Авторы делают вывод, что для улучшения продолжительности и качества жизни пациентов c сердечно-сосудистыми заболеваниями, снижения риска и частоты осложнений и показателей смертности необходимо подробнее исследовать функцию эндотелия и искать пути медикаментозной коррекции с учетом патогенетических механизмов ее формирования.
1. Park K-H, Park WJ. Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches. Journal of Korean Medical Science. 2015;30(9):1213–25. DOI: 10.3346/ jkms.2015.30.9.1213
2. Capone C, Faraco G, Coleman C, Young CN, Pickel VM, Anrather J et al. Endothelin 1 – Dependent Neurovascular Dysfunction in Chronic Intermittent Hypoxia. Hypertension. 2012;60 (1):106–13. DOI: 10.1161/HYPERTENSIONAHA.112.193672
3. Cavailles A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S et al. Comorbidities of COPD. European Respiratory Review. 2013;22(130):454–75. DOI: 10.1183/09059180.00008612
4. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS et al. Endothelin. Pharmacological Reviews. 2016;68(2):357–418. DOI: 10.1124/pr.115.011833
5. Babushkina I. V., Sergeeva A. S., Pivovarov Yu. I., Kurilskaya T. E., Koryakina L. B. Structural and Functional Properties of Vascular Endothelium. Kardiologiia. 2015;55(2):82–6.. DOI: 10.18565/cardio.2015.2.82-86
6. Vorobeva E. N., Vorobуev R. I., Sharlaeva E. A., Fomicheva M. L., Sokolova G. G., Kazyzaeva A. S. et al. Endothelial dysfunction in cardiovascular diseases: risk factors, methods of diagnosis and correction. Acta Biologica Sibirica. 2016;2(1):21–40.
7. Bulaeva N. A., Golukhova E. Z. Endothelial dysfunction and oxidative stress: role in the development of cardiovascular disease. Creative cardiology. 2013;1:14–22.
8. Mordi I, Mordi N, Delles C, Tzemos N. Endothelial dysfunction in human essential hypertension: Journal of Hypertension. 2016;34(8):1464–72. DOI: 10.1097/HJH.0000000000000965
9. Münzel T, Camici GG, Maack C, Bonetti NR, Fuster V, Kovacic JC. Impact of Oxidative Stress on the Heart and Vasculature. Journal of the American College of Cardiology. 2017;70(2):212–29. DOI: 10.1016/j. jacc.2017.05.035
10. Gungor ZB, Sipahioglu N, Sonmez H, Ekmekci H, Toprak S, Ayaz G et al. Endothelial Dysfunction Markers in Low Cardiovascular Risk Individuals: Comparison of Males and Females. Journal of Medical Biochemistry. 2017;36(1):62–72. DOI: 10.1515/jomb-2016-0030
11. Panza JA. Endothelial dysfunction in essential hypertension. Clinical Cardiology. 1997;20(11 Suppl 2):II-26–33. PMID: 9422849
12. Strisciuglio T, De Luca S, Capuano E, Luciano R, Niglio T, Trimarco B et al. Endothelial Dysfunction: Its Clinical Value and Methods of Assessment. Current Atherosclerosis Reports. 2014;16(6). DOI: 10.1007/s11883-014-0417-1
13. Golukhova E. Z., Aliyeva A. M., Kakuchaya T. T., Arakelyan G. G., Bulae va N. I. Endothelin – modern biomarker of cardiovascular diseases. Creative cardiology. 2011;2:97–103.
14. Münzel T, Gori T, Keaney JF, Maack C, Daiber A. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. European Heart Journal. 2015;36(38):2555–64. DOI: 10.1093/eurheartj/ehv305
15. Smiljic S. The clinical significance of endocardial endothelial dysfunction. Medicina. 2017;53(5):295–302. DOI: 10.1016/j.medici.2017.08.003
16. Talavera-Adame D. Endothelium-derived essential signals involved in pancreas organogenesis. World Journal of Experimental Medicine. 2015;5(2):40. DOI: 10.5493/wjem.v5.i2.40
17. Ahmineeva A. H. Biochemical markers of endothelial dysfunction in chronic obstructive pulmonary disease in combination with hypertonic disease, coronary heart disease. Therapeutic Archive. 2014;86(3):20–3.
18. Mel’nikova Yu. S., Makarova T. P. Endothelial dysfunction as a сentral link chronic diseases pathogenesis. Kazan medical journal. 2015;96(4):659–65.
19. Popova M. A., Terentyeva N. N., Dolgopolova D. A., Marenina T. V. Endothelial dysfunction with stable angina and myocardial infarction in combination with chronic obstructive pulmonary disease. Bulletin of Siberian medicine. 2015;14(6):68–74.
20. Lapshina L. A., Molodin V. I., Shevchenko O. S. Endothelial dysfunction in the initial stages of arterial hypertension and methods of its non-drug correction. Ukrainian therapeutic journal. 2001;(4):39–42.
21. Zimnitskaya O. V., Petrova M. M., Kaskaeva D. S. Plasma markers of endothelial dysfunction in hypertension (review). In the world of scientific discoveries. 2015;4(64):204–30.
22. Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Douma S. Clinical Significance of Endothelial Dysfunction in Essential Hypertension. Current Hypertension Reports. 2015;17(11):85. DOI: 10.1007/s11906-015-0596-3
23. Petrishchev N. N., Vasina L. V., Sapegin A. A., Fabrichnikov S. V., Morozova L. Yu. Diagnostic significance of determining the content of endothelial damage factors to assess the severity of endothelial dysfunction in acute coronary syndrome. Clinical hospital. 2015;1(11):41–5.
24. Kolettis TM, Barton M, Langleben D, Matsumura Y. Endothelin in Coronary Artery Disease and Myocardial Infarction: Cardiology in Review. 2013;21(5):249–56. DOI: 10.1097/CRD.0b013e318283f65a
25. Shao D, Park JES, Wort SJ. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacological Research. 2011;63(6):504–11. DOI: 10.1016/j.phrs.2011.03.003
26. Vignon-Zellweger N, Heiden S, Miyauchi T, Emoto N. Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sciences. 2012;91(13–14):490–500. DOI: 10.1016/j.lfs.2012.03.026
27. Almagro P, Cabrera FJ, Diez J, Boixeda R, Alonso Ortiz MB, Murio C et al. Comorbidities and Short-term Prognosis in Patients Hospitalized for Acute Exacerbation of COPD. Chest. 2012;142(5):1126–33. DOI: 10.1378/chest.11-2413
28. Selikhova M. A., Kuvaev V. S. Up-to-date state of the problem concerning endothelial dysfunction correction in COPD. Aspirantskiy Vestnik Povolzhiya. 2012;5–6:66–8.
29. Ambrosino P, Lupoli R, Iervolino S, De Felice A, Pappone N, Storino A et al. Clinical assessment of endothelial function in patients with chronic obstructive pulmonary disease: a systematic review with meta-analysis. Internal and Emergency Medicine. 2017;12(6):877–85. DOI: 10.1007/ s11739-017-1690-0
30. Mannino DM, Sanderson WT. Using Big Data to Reveal Chronic Respiratory Disease Mortality Patterns and Identify Potential Public Health Interventions. JAMA. 2017;318(12):1112–4. DOI: 10.1001/ jama.2017.11746
31. Kirkham PA, Barnes PJ. Oxidative Stress in COPD. Chest. 2013;144(1):266–73. DOI: 10.1378/chest.12-2664
32. Ives SJ, Harris RA, Witman MAH, Fjeldstad AS, Garten RS, McDaniel J et al. Vascular Dysfunction and Chronic Obstructive Pulmonary Disease: The Role of Redox Balance. Hypertension. 2014;63(3):459–67. DOI: 10.1161/HYPERTENSIONAHA.113.02255
33. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. European Respiratory Journal. 2008;32(4):962–9. DOI: 10.1183/09031936.00012408
34. Rahman T, Hosen I, Islam MMT, Shekhar HU. Oxidative stress and human health. Advances in Bioscience and Biotechnology. 2012;03(07):997–1019. DOI: 10.4236/abb.2012.327123
35. Shpagin I. S., Kotova O. S., Pospelova T. I., Gerasimenko O. N., Shpagina L. A., Ermakova M. A. Chronic obstructive pulmonary disease in combination with essential arterial hypertension: clinical, functional and molecular genetic features. Bulletin of modern clinical medicine. 2016;9(4):56–65.
36. Kushnarenko N. N., Govorin A. V. Clinical significance of endothelial dysfunction and insulin resistance syndrome in patients with gout with hypertension. Rational Pharmacotherapy in Cardiology. 2013;9(5):482–7.
37. Libov I. A., Kiselev M. V., Smirnova V. Yu., Avtandilov A. G., Yakovlev V. N. Prognostic role of endothelin-1 and possibilities of its correction in patients with unstable angina. Russian medical journal. 2008;16(4):211–6.
38. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet (London, England). 1992;340(8828):1111–5. PMID: 1359209
39. Golikov P. P. Nitric Oxide in the clinic of urgent diseases. – M.: Medpraktika-M; 179 p.. ISBN 978-5-901654-84-2
40. Golikov A. P., Lukyanov M. M., Polumiskov V. Yu., Golikov P. P., Davydov B. V., Rudnev D. V. New possibilities of treatment and prevention of hypertensive crises in patients with a combination of hypertension and coronary heart disease. Cardiovascular therapy and prevention. 2005;4(3–1):10–6.
41. Okrut I. E., Shakirova D. A., Veselova T. A. Change of nitric oxide concentration and free-radical oxidation activity in the blood of breast cancer patients. Vestnik of Lobachevsky University of Nizhni Novgorod. 2011;5(1):118–21.
42. Okrut I. E., Kontorshchikova K. N., Dautova D. A. Effect of ozonetherapy on the concentration of nitrogen oxide in hypertension. Radicals and antioxidants. 2016;3(3):217–9.
43. Okrut I. E., Dautova D. A. Nitric Oxide as an indicator of free radical oxidation activity in metabolic syndrome. Innovative science. 2015;8–2(8):132–5.
44. Djordjevic D, Cubrilo D, Macura M, Barudzic N, Djuric D, Jakovljevic V. The influence of training status on oxidative stress in young male handball players. Molecular and Cellular Biochemistry. 2011;351(1–2):251–9. DOI: 10.1007/s11010-011-0732-6
45. Su JB. Vascular endothelial dysfunction and pharmacological treatment. World Journal of Cardiology. 2015;7(11):719–41. DOI: 10.4330/wjc. v7.i11.719
46. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97. PMID: 12479763
47. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255–64. PMID: 2046107
48. Kechedgieva N. P., Tripoten M. I., Sychev A. V., Filatov D. N., Narusov O. Yu., Skvotzov А. А. et al. Feasible mechanisms of the positive action of simvastatin for integrated treatment of CHF patients with ischemic etiology. Russian Heart Failure Journal. 2011;12(5):286–93.
49. Mikhin V. P., Zhilyaeva Yu. A., Kharchenko A. V. Changes in the functional state of vascular endothelium in patients with ischemic heart disease during treatment with generic statins. Kursk Scientific and Practical Bulletin ‘Man and His Health’. 2012;3:65–71.
50. Klimushina M. V., Gumanova N. D., Gorshkov A. Yu., Gavrilova N. E., Metelskaya V. A., Boytsov S. A. Endothelium-protective function of statins in men and women with coronary atherosclerosis. Rational pharmacotherapy in cardiology. 2016;12(5):503–8.
51. Liu G, Zheng X-X, Xu Y-L, Lu J, Hui R-T, Huang X-H. Effects of Lipophilic Statins for Heart Failure: A Meta-analysis of 13 Randomised Controlled Trials. Heart, Lung and Circulation. 2014;23(10):970–7. DOI: 10.1016/j. hlc.2014.05.005
52. Pauriah M, Elder DHJ, Ogston S, Noman AYS, Majeed A, Wyatt JC et al. High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. Heart. 2014;100(11):867–72. DOI: 10.1136/heartjnl-2013-304678
53. Kremkova M. M., Grachev A. V., Alyavi B. A., Yakubov M. M., Masri M. A. A Comparative Assesment of Valsartan and Lisinopril Effects on Sistolic and Diastolic Function of the Leſt Ventricular in Patients with Acute Q-Infarction. Kardiologiia. 2005;45(3):85–6.
54. Safronova V. V., Maksimov N. I., Timonin D. V., Chernykh Yu. V., Baranova S. P. Clinical efficacy of Eprosartan in young hypertensive male patients. Arterial Hypertension. 2011;17(1):17–23.
55. Khafizova L. S., Hamidullaev G. A., Kurbanov D. R., Karimova B. Sh. Efficiency of Double Combined Therapy in Hypertensive Patients with High Cardiovascular Risk. Arterial Hypertension. 2015;4(42):58–64.
56. Britov A. N. Endothelial dysfunction and the role of nitrates and beta-blockers in its correction in coronary heart disease. Rational Pharmacotherapy in Cardiology. 2016;12(2):234–8.
57. Knyazeva L. V., Belenkov Yu. N., Privalova E. V., Zheleznykh E. A., Azizova O. A., Aseychev A. V. et al. Impact of β-blockers on lipid and protein oxidation in patients with chronic heart failure. Cardiology and cardiovascular surgery. 2010;3(1):45–51.